Investors & Media

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients Ionis plans to independently bring donidalorsen to U.S. patients if approved Donidalorsen Phase 3 results expected in the first half of 2024 CARLSBAD, Calif. , Dec.

Read more
You are now leaving https://www.ionispharma.com to visit